Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution

George R. Simon, John C. Ruckdeschel, Charles Williams, Alan Cantor, Alberto Chiappori, Caio M Rocha Lima, Scott Antonia, Eric Haura, Henry Wagner, Lary Robinson, Eric Sommers, Michael Alberts, Gerold Bepler

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8%, but an additional 53.5% of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35%. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35% in a cohort of patients who were able to take the drug for at least 12 weeks.

Original languageEnglish
Pages (from-to)388-395
Number of pages8
JournalCancer Control
Volume10
Issue number5
StatePublished - Sep 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Survival Rate
Survival
gefitinib
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Disease-Free Survival
Diarrhea
Histology
Adenocarcinoma
Carcinoma
Skin
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Simon, G. R., Ruckdeschel, J. C., Williams, C., Cantor, A., Chiappori, A., Lima, C. M. R., ... Bepler, G. (2003). Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution. Cancer Control, 10(5), 388-395.

Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer : Experience From a Single Institution. / Simon, George R.; Ruckdeschel, John C.; Williams, Charles; Cantor, Alan; Chiappori, Alberto; Lima, Caio M Rocha; Antonia, Scott; Haura, Eric; Wagner, Henry; Robinson, Lary; Sommers, Eric; Alberts, Michael; Bepler, Gerold.

In: Cancer Control, Vol. 10, No. 5, 01.09.2003, p. 388-395.

Research output: Contribution to journalArticle

Simon, GR, Ruckdeschel, JC, Williams, C, Cantor, A, Chiappori, A, Lima, CMR, Antonia, S, Haura, E, Wagner, H, Robinson, L, Sommers, E, Alberts, M & Bepler, G 2003, 'Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution', Cancer Control, vol. 10, no. 5, pp. 388-395.
Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Lima CMR et al. Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution. Cancer Control. 2003 Sep 1;10(5):388-395.
Simon, George R. ; Ruckdeschel, John C. ; Williams, Charles ; Cantor, Alan ; Chiappori, Alberto ; Lima, Caio M Rocha ; Antonia, Scott ; Haura, Eric ; Wagner, Henry ; Robinson, Lary ; Sommers, Eric ; Alberts, Michael ; Bepler, Gerold. / Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer : Experience From a Single Institution. In: Cancer Control. 2003 ; Vol. 10, No. 5. pp. 388-395.
@article{8ee27879d1f94dee85083c712596eaf0,
title = "Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience From a Single Institution",
abstract = "Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8{\%}, but an additional 53.5{\%} of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35{\%}. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35{\%} in a cohort of patients who were able to take the drug for at least 12 weeks.",
author = "Simon, {George R.} and Ruckdeschel, {John C.} and Charles Williams and Alan Cantor and Alberto Chiappori and Lima, {Caio M Rocha} and Scott Antonia and Eric Haura and Henry Wagner and Lary Robinson and Eric Sommers and Michael Alberts and Gerold Bepler",
year = "2003",
month = "9",
day = "1",
language = "English",
volume = "10",
pages = "388--395",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "5",

}

TY - JOUR

T1 - Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer

T2 - Experience From a Single Institution

AU - Simon, George R.

AU - Ruckdeschel, John C.

AU - Williams, Charles

AU - Cantor, Alan

AU - Chiappori, Alberto

AU - Lima, Caio M Rocha

AU - Antonia, Scott

AU - Haura, Eric

AU - Wagner, Henry

AU - Robinson, Lary

AU - Sommers, Eric

AU - Alberts, Michael

AU - Bepler, Gerold

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8%, but an additional 53.5% of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35%. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35% in a cohort of patients who were able to take the drug for at least 12 weeks.

AB - Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8%, but an additional 53.5% of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35%. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35% in a cohort of patients who were able to take the drug for at least 12 weeks.

UR - http://www.scopus.com/inward/record.url?scp=10744229425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229425&partnerID=8YFLogxK

M3 - Article

C2 - 14581894

AN - SCOPUS:10744229425

VL - 10

SP - 388

EP - 395

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 5

ER -